German Medtechs Search For Blue Skies Amid ‘Cloudy Outlook’ For Industry − Medica 2023
Regulatory compliance is no longer the only pressing issue for medtechs in Germany
While revenues are looking healthier at last, a host of issues in the post-COVID readjustment phase still weigh heavily on medtech manufacturers in Germany, chief among which is EU and national over-regulation. Hospital reform and the digital shift are also on a long list of priority issues to monitor and tackle if Germany’s industrial base is to remain preeminent, said BVMed chief executive Marc-Pierre Möll.
You may also be interested in...
Higher logistics and energy costs are putting medtech P&Ls under pressure, and compliance with the EU MDR is draining any remaining surplus. Sustainability compliance is another cost to factor in, says BVMed chief executive Marc-Pierre Möll in part 2 of his interview with Medtech Insight at Medica 2023.
Three central European industry associations have agreed to develop joint initiatives and form a collective voice with which to lobby decision-makers on medtech themes of mutual interest.
The COVID-19 threat is abating and control measures are easing, but government commitments made at the height of the pandemic to forearm against future health care emergencies should not be abandoned. That is the position of both the German Advisory Council on Health and Care and the IVD industry.